BOSTON--(BUSINESS WIRE)--MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today presented positive results from an analytical validation study demonstrating the analytical accuracy, reproducibility, and precision of its MetaSite Breast™ test at the Tumor Metastasis meeting of the American Association for Cancer Research (AACR) in Austin, Texas.
